Research programme: C5a receptor antagonists - Arana TherapeuticsAlternative Names: PMX-025
Latest Information Update: 21 Aug 2009
At a glance
- Originator Peptech
- Mechanism of Action Complement C5a inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Age-related macular degeneration; Autoimmune disorders; Inflammatory bowel diseases
Most Recent Events
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 07 Sep 2005 Preclinical trials in Inflammatory bowel disease in Australia (unspecified route)